Anti-CUEDC2 Antibody

CUE domain-containing 2 (CUEDC2) is a protein involved in the regulation of the cell cycle, inflammation, and tumorigenesis and is highly expressed in many types of tumors. CUEDC2 is phosphorylated by Cdk1 during mitosis and promotes the release of anaphase-promoting complex or cyclosome (APC/C) from checkpoint inhibition. CUEDC2 is also known to interact with IkB kinase alpha (IKKalpha) and IKKbeta and has an inhibitory role in the activation of transcription factor nuclear factor-kappaB. Moreover, CUEDC2 plays an important role in downregulating the expression of hormone receptors estrogen receptor-alpha and progesterone receptor, thereby impairing the responsiveness of breast cancer to endocrine therapies. The expression level of CUEDC2 has an inverse correlation with imatinib resistance and activity of NF-kappaB signaling pathway in CML cells, CUEDC2 could regulate imatinib sensitivity in CML cells at least partially through NF-kappaB signaling pathway. CUEDC2 may be a promising biomarker to evaluate the progression of serous ovarian carcinoma and to predict likely relapse of ovarian serous carcinoma. The decreased expression of CUEDC2 contributes to tumor growth in lung adenocarcinoma, leading to a poor clinical outcome.